Skip to main content
Premium Trial:

Request an Annual Quote

Sanofi-GSK Vaccine Results

Sanofi and GlaxoSmithKline say two doses of their more traditional protein-based SARS-CoV-2 vaccine is 75 percent effective in protecting against moderate-to-severe COVID-19, the New York Times reports.

The two pharmaceutical companies announced in April 2020 that they would be working together to develop a SARS-CoV-2 vaccine but said in December 2020 that their candidate vaccine did not produce a high enough immune response in early-stage trials, leading to a delay in its development. Then in May 2021, the companies reported promising results after reformulating their vaccine.

Sanofi and GSK now say two doses of their vaccine, dubbed Vidprevtyn and given three weeks apart, is 58 percent effective at preventing COVID-19 symptoms, 75 percent effective at preventing moderate or severe disease, and 100 percent effective against severe disease and hospitalizations, according to CNN.

This, CNN says is not as high as what the mRNA-based vaccines from Moderna and Pfizer-BioNTech reported, but it notes that the vaccines were tested under different conditions. Further, Sanofi and GSK also said that the vaccine worked well as a mix-and-match booster.

Filed under